ASP Isotopes (NASDAQ:ASPI) Trading Up 7.6% - Should You Buy?

ASP Isotopes Inc. (NASDAQ:ASPI - Get Free Report)'s stock price traded up 7.6% during trading on Thursday . The company traded as high as $7.49 and last traded at $7.38. 440,366 shares changed hands during mid-day trading, a decline of 83% from the average session volume of 2,576,629 shares. The stock had previously closed at $6.86.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group upped their target price on shares of ASP Isotopes from $8.50 to $11.00 and gave the company a "buy" rating in a report on Wednesday, May 21st.

ASP Isotopes Price Performance

The firm's fifty day moving average is $7.13 and its 200-day moving average is $5.75. The company has a current ratio of 7.21, a quick ratio of 7.17 and a debt-to-equity ratio of 0.80.

Insider Buying and Selling

In related news, COO Robert Ainscow sold 66,668 shares of the stock in a transaction dated Thursday, April 17th. The shares were sold at an average price of $5.62, for a total transaction of $374,674.16. Following the completion of the transaction, the chief operating officer now directly owns 1,419,992 shares of the company's stock, valued at $7,980,355.04. This represents a 4.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Paul Elliot Mann sold 316,667 shares of the stock in a transaction dated Tuesday, April 15th. The stock was sold at an average price of $5.75, for a total transaction of $1,820,835.25. Following the transaction, the chief executive officer now directly owns 7,948,787 shares of the company's stock, valued at $45,705,525.25. This represents a 3.83% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 766,667 shares of company stock valued at $4,358,502 over the last ninety days. Corporate insiders own 21.40% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Two Sigma Investments LP acquired a new position in ASP Isotopes during the fourth quarter worth about $1,980,000. JPMorgan Chase & Co. grew its position in ASP Isotopes by 854.6% during the fourth quarter. JPMorgan Chase & Co. now owns 211,893 shares of the company's stock worth $960,000 after buying an additional 189,697 shares during the period. BNP Paribas Financial Markets acquired a new position in ASP Isotopes during the fourth quarter worth about $34,000. Price T Rowe Associates Inc. MD grew its position in ASP Isotopes by 14.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 21,646 shares of the company's stock worth $99,000 after buying an additional 2,757 shares during the period. Finally, ProShare Advisors LLC acquired a new position in ASP Isotopes during the fourth quarter worth about $67,000. 16.80% of the stock is currently owned by institutional investors and hedge funds.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.